Previous findings have demonstrated that DNMT3A mutation variants could serve as potential biomarkers for HMA response in MDS and AML patients, with implications for risk stratification and therapeutic choices (36, 46). This evidence concerns the gene DNMT3A and acute myeloid leukemia.